Ivan M. Borrello, MD, discusses treatment for patients with indolent versus aggressive relapsed multiple myeloma.
Ivan M. Borrello, MD
Advertisement
Articles by Ivan M. Borrello, MD
Ivan M. Borrello, MD, discusses the current multiple myeloma treatment paradigm.
Ivan M. Borrello, MD, associate professor of oncology, Johns Hopkins Medicine, discusses the use of selinexor (Xpovio) in the treatment of patients with penta-refractory multiple myeloma.
Advertisement
Latest Updated Articles
Dr. Borrello on Selinexor in Penta-Refractory Multiple MyelomaPublished: September 21st 2019 | Updated:
Dr. Borrello Sheds Light on the Multiple Myeloma Treatment ParadigmPublished: October 31st 2019 | Updated:
Dr. Borello on Treating Indolent Versus Aggressive Relapsed Multiple MyelomaPublished: November 12th 2019 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
3
Dr Spencer on First-Line Chemo Selection in Metastatic Pancreatic Adenocarcinoma
4
2025 Data Across Gynecologic, Lung, and Hematologic Cancers Reshape Treatment Landscapes
5